Evidence map›Paper›PMID 34313468›Full record

ArticleRadiology2021

Post-Acute Sequelae of COVID-19 Pneumonia: Six-month Chest CT Follow-up.

Damiano Caruso, Gisella Guido, Marta Zerunian, Tiziano Polidori, Elena Lucertini, Francesco Pucciarelli, Michela Polici, Carlotta Rucci, Benedetta Bracci, Matteo Nicolai and 3 more

Registry-linked trialOpen access · greenAbstract readComment
In one paragraph

Article in Radiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05823896 (An Interventional, Double-Blinded, 2-Arm Study to Investigate the Efficacy of Orally Administered Nirmatrelvir/Ritonavir Compared with Placebo/Ritonavir in Non-hospitalized Adult Participants Suffering from Post-COVID), which is not on this map. Cited by 89 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed, 8 pooled it
17.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05823896 phase2completednot on this mapstarted 2023, after this paper: background citation

An Interventional, Double-Blinded, 2-Arm Study to Investigate the Efficacy of Orally Administered Nirmatrelvir/Ritonavir Compared with Placebo/Ritonavir in Non-hospitalized Adult Participants Suffering from Post-COVID

TypeinterventionalSponsorKarolinska InstitutetRan2023 to 2024Enrolled219ConditionsPost-COVID-19 Syndrome, Long COVID, Long Covid19, COVID-19ArmsNirmatrelvir/ritonavir, Placebo/ritonavir
3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 8 syntheses or guidelines pooled it, 138 citations in OpenAlex.

  1. Global prevalence of post-COVID-19 condition: a systematic review and meta-analysis of prospective evidence.Health promotion and chronic disease prevention in Canada : research, policy and practice · 2025
    Pooled it
  2. SARS-CoV-2 post-acute sequelae in previously hospitalised patients: systematic literature review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2023
    Pooled it
  3. Post-COVID-19 dyspnoea and pulmonary imaging: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2023
    Pooled it
  4. Comparison of Long COVID-19 Caused by Different SARS-CoV-2 Strains: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2022
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Long-Term Consequences of COVID-19 at 6 Months and Above: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2022
    Pooled it
  8. Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022
    Pooled it
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Observational
  19. Observational
  20. Article

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Damiano CarusoFrom the Department of Surgical and Medical Sciences and Translational Medicine, Sapienza University of Rome-Sant'Andrea University Hospital, Via di Grottarossa, 1035-1039, 00189 Rome, Italy.ORCID 0000-0001-9285-4764
Gisella GuidoFrom the Department of Surgical and Medical Sciences and Translational Medicine, Sapienza University of Rome-Sant'Andrea University Hospital, Via di Grottarossa, 1035-1039, 00189 Rome, Italy.ORCID 0000-0002-0711-2975
Marta ZerunianFrom the Department of Surgical and Medical Sciences and Translational Medicine, Sapienza University of Rome-Sant'Andrea University Hospital, Via di Grottarossa, 1035-1039, 00189 Rome, Italy.ORCID 0000-0003-4635-7999
Tiziano PolidoriFrom the Department of Surgical and Medical Sciences and Translational Medicine, Sapienza University of Rome-Sant'Andrea University Hospital, Via di Grottarossa, 1035-1039, 00189 Rome, Italy.ORCID 0000-0002-4633-6760
Elena LucertiniFrom the Department of Surgical and Medical Sciences and Translational Medicine, Sapienza University of Rome-Sant'Andrea University Hospital, Via di Grottarossa, 1035-1039, 00189 Rome, Italy.ORCID 0000-0002-5631-2666
Francesco PucciarelliFrom the Department of Surgical and Medical Sciences and Translational Medicine, Sapienza University of Rome-Sant'Andrea University Hospital, Via di Grottarossa, 1035-1039, 00189 Rome, Italy.ORCID 0000-0001-7263-1125
Michela PoliciFrom the Department of Surgical and Medical Sciences and Translational Medicine, Sapienza University of Rome-Sant'Andrea University Hospital, Via di Grottarossa, 1035-1039, 00189 Rome, Italy.ORCID 0000-0001-7331-6901
Carlotta RucciFrom the Department of Surgical and Medical Sciences and Translational Medicine, Sapienza University of Rome-Sant'Andrea University Hospital, Via di Grottarossa, 1035-1039, 00189 Rome, Italy.ORCID 0000-0003-3793-2277
Benedetta BracciFrom the Department of Surgical and Medical Sciences and Translational Medicine, Sapienza University of Rome-Sant'Andrea University Hospital, Via di Grottarossa, 1035-1039, 00189 Rome, Italy.ORCID 0000-0002-2017-8493
Matteo NicolaiFrom the Department of Surgical and Medical Sciences and Translational Medicine, Sapienza University of Rome-Sant'Andrea University Hospital, Via di Grottarossa, 1035-1039, 00189 Rome, Italy.ORCID 0000-0003-0238-5461
Antonio CremonaFrom the Department of Surgical and Medical Sciences and Translational Medicine, Sapienza University of Rome-Sant'Andrea University Hospital, Via di Grottarossa, 1035-1039, 00189 Rome, Italy.ORCID 0000-0002-9944-0596
Chiara De DominicisFrom the Department of Surgical and Medical Sciences and Translational Medicine, Sapienza University of Rome-Sant'Andrea University Hospital, Via di Grottarossa, 1035-1039, 00189 Rome, Italy.ORCID 0000-0003-3789-1460
Andrea LaghiFrom the Department of Surgical and Medical Sciences and Translational Medicine, Sapienza University of Rome-Sant'Andrea University Hospital, Via di Grottarossa, 1035-1039, 00189 Rome, Italy.ORCID 0000-0002-3091-7819
Azienda Ospedaliera Sant'Andrea · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background The long-term post-acute pulmonary sequelae of COVID-19 remain unknown. Purpose To evaluate lung injury in patients affected by COVID-19 pneumonia at the 6-month follow-up CT examination compared with the baseline chest CT examination. Materials and Methods From March 19, 2020, to May 24, 2020, patients with moderate to severe COVID-19 pneumonia who had undergone baseline chest CT were prospectively enrolled at their 6-month follow-up. The CT qualitative findings, semiquantitative Lung Severity Score (LSS), and the well-aerated lung volume at quantitative chest CT (QCCT) analysis were analyzed. The performance of the baseline LSS and QCCT findings for predicting fibrosis-like changes (reticular pattern and/or honeycombing) at the 6-month follow-up chest CT examination was tested by using receiver operating characteristic curves. Univariable and multivariable logistic regression analyses were used to test clinical and radiologic features that were predictive of fibrosis-like changes. The multivariable analysis was performed with clinical parameters alone (clinical model), radiologic parameters alone (radiologic model), and the combination of clinical and radiologic parameters (combined model). Results One hundred eighteen patients who had undergone baseline chest CT and agreed to undergo follow-up chest CT at 6 months were included in the study (62 women; mean age, 65 years ± 12 [standard deviation]). At follow-up chest CT, 85 of 118 (72%) patients showed fibrosis-like changes and 49 of 118 (42%) showed ground-glass opacities. The baseline LSS (>14) and QCCT findings (≤3.75 L and ≤80%) showed excellent performance for predicting fibrosis-like changes at follow-up chest CT. In the multivariable analysis, the areas under the curve were 0.89 (95% CI: 0.77, 0.96) for the clinical model, 0.81 (95% CI: 0.68, 0.9) for the radiologic model, and 0.92 (95% CI: 0.81, 0.98) for the combined model. Conclusion At 6-month follow-up chest CT, 72% of patients showed late sequelae, in particular fibrosis-like changes. The baseline Lung Severity Score and the well-aerated lung volume at quantitative chest CT (QCCT) analysis showed excellent performance for predicting fibrosis-like changes at the 6-month chest CT (area under the curve, >0.88). Male sex, cough, lymphocytosis, and the well-aerated lung volume at QCCT analysis were significant predictors of fibrosis-like changes at 6 months, demonstrating an inverse correlation (area under the curve, 0.92). © RSNA, 2021 See also the editorial by Wells and Devaraj in this issue.

Indexed as

COVID-19AgedFemaleFollow-Up StudiesHumansLungMaleRetrospective StudiesSARS-CoV-2Tomography, X-Ray Computed

Identifiers

PMID34313468
PMCPMC8335814
OpenAlexW3186536821

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.